We know that cannabis and CBD products are often not what they seem. In fact, a recent study showed that several cannabis companies exploit their academic partnerships for marketing purposes.
In case you missed it, recent studies and investigations have found that many cannabis and CBD products are often mislabeled, frequently containing more than advertised:
One analysis highlights several concerns on the mislabeling front: CBD Oracle purchased 53 products from 48 different brands manufactured across 18 states. Testing of products’ THC or Delta-9 THC content found that nearly half of these products were mislabeled, with THC content more than 15% higher or lower than what the labels suggested. Some products were extremely strong, with up to 40 milligrams of THC per individual serving, which is four times stronger than the 10 mg/THC serving limits imposed on state-regulated cannabis edibles. Nearly every product was sold without verifying the buyer’s age.
An additional study also found that out of 52 CBD sleep products, 60% contained the wrong amounts of CBD, CBN, or melatonin.
A recent Minnesota CBS affiliate WCCO’s investigation and testing found several discrepancies in popular CBD and Delta-8 products. “Some are high, some are low, some are over the legal limit, and some are missing compounds that they claim,” said Emily Hoffman of Legend Technical Services in St. Paul, Minnesota.
These findings are obviously very concerning for consumers. Inaccurate dosage and labeling could be incredibly harmful to adults, children, and pets who consume these products, and could result in dangerous health consequences. The time is now for the FDA to act on cannabis and cannabis-derived consumer products. Consumers must feel confident that the products they are buying are safe, accurately labeled, and will not cause undue harm.